Vanguard Global Advisers
TXG icon

Vanguard Global Advisers’s 10x Genomics TXG Stock Holding History

Vanguard Global Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.17M Sell
56,496
-3,494
-6% -$91.6K ﹤0.01% 1205
2026
Q1 		$1.27M Buy
+59,990
New +$1.2M ﹤0.01% 1494

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Global Advisers's TXG Position: Q2 2026 in Review

Vanguard Global Advisers reduced its 10x Genomics (TXG) stake by 5.8% in Q2 2026, selling an estimated $91.6K and leaving 56,496 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1205.

Vanguard Global Advisers first reported a position in TXG in Q1 2026 and has held it in 2 quarters since. 384 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Vanguard Global Advisers held 56,496 shares of 10x Genomics worth $2.17M as of Q2 2026.
  • Vanguard Global Advisers sold 3,494 10x Genomics shares in Q2 2026, an estimated $91.6K.
  • 10x Genomics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1205 holding.
  • Vanguard Global Advisers first reported a position in 10x Genomics in Q1 2026 and has held it in 2 quarters since.
  • 384 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.